In vitro, research conducted on HCC827, HCC827ER, and H1975 lung cancer cells using a combination treatment of siRNA STAT3 with erlotinib (epidermal growth factor receptor tyrosine kinase inhibitor) revealed an association of erlotinib resistance with STAT3 activation [140]. This evidence concerns the gene STAT3 and lung cancer.